Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-06-10
DOI
10.1016/j.annonc.2022.05.521
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- (2021) Nikhil C. Munshi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma
- (2021) Gloria Iacoboni et al. Cancer Medicine
- CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma
- (2021) Kai Rejeski et al. BLOOD
- Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study
- (2021) Stephen J Schuster et al. LANCET ONCOLOGY
- Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
- (2021) Caron A Jacobson et al. LANCET ONCOLOGY
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- (2020) Michael Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of Commercial anti‐CD19 CAR T Cell Therapy for Patients with Relapsed/Refractory Aggressive B Cell Lymphoma in a European center
- (2020) Pierre Sesques et al. AMERICAN JOURNAL OF HEMATOLOGY
- Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
- (2020) Carlos A. Ramos et al. JOURNAL OF CLINICAL ONCOLOGY
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- CAR‐T TREK through the lymphoma universe, to boldly go where no other therapy has gone before
- (2020) Guido Ghilardi et al. BRITISH JOURNAL OF HAEMATOLOGY
- The response to lymphodepletion impacts PFS in aggressive non-Hodgkin lymphoma patients treated with CD19 CAR-T cells
- (2019) Alexandre V. Hirayama et al. BLOOD
- Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management
- (2019) Preetesh Jain et al. AMERICAN JOURNAL OF HEMATOLOGY
- Diagnosis and management of follicular lymphoma: A comprehensive review
- (2019) Reyad Dada EUROPEAN JOURNAL OF HAEMATOLOGY
- Fludarabine and neurotoxicity in engineered T-cell therapy
- (2018) Kate L. Lowe et al. GENE THERAPY
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
- (2016) R. Gardner et al. BLOOD
- First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
- (2016) Barbara Eichhorst et al. LANCET ONCOLOGY
- Fludarabine: A review of the clear benefits and potential harms
- (2013) Joshua Lukenbill et al. LEUKEMIA RESEARCH
- Cyclophosphamide and cancer: golden anniversary
- (2009) Ashkan Emadi et al. Nature Reviews Clinical Oncology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now